myirislogo
14 November, 2019 07:17 IST
My Last 5 Scrips
Company BSE Price (Rs) % Chg
Adani Ports 370.65 4.36
Power Grid 189.15 1.33
Tata Motors 170.60 0.81
State Bank O 306.55 3.69
Tata Stl 396.85 1.15
Clear All Clear Last
   
NSE Live
Nifty Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Nse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
BSE Live
BSE30 Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Bse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
Watch
Sector Watch
Economy Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Research
Research Reports
Snapshot-Lupin Limited
Lupin Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs
BSE:500257NSE:LUPINBloomberg:LPC@INReuters:LUPN.BO
Market Lot: 1Face Value: 2ISIN Demat: INE326A01037
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
11-FEB-19 Pharma major Lupin announced the completion of the United States Food and Drug Administration (U.S. FDA) inspection at its Goa manufacturing facility. The inspection was carried out between January 28 to February 8, 2019. 07-FEB-19 Pharma major Lupin announced that it has received approval for its Tadalafil Tablets USP, 20 mg from the United States Food and Drug Administration (FDA) to market a generic version of Eli Lilly and Compan...   More..
Business Profile Future Plans
CEO Talk
Lupin Ltd is focusing on manufacturing products with high technology barriers through the non-infringing route.   D. B. Gupta
One To One
Recent news
Latest News
Lupin receives approval for Methylprednisolone tablets USP  -IRIS 25-Feb-19
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)31-Mar-2016(12)31-Mar-2015 (12)31-Mar-2014(12)
Net sales 108100.1096115.4087771.80
Other Income1938.801806.304882.20
Total Income110038.9097921.7092654.00
Cost of goods sold72480.1063792.2060998.90
OPBDIT37558.8034129.5031655.10
PAT28850.7023973.5023242.20
Gross Block---
Equity capital901.20899.00896.80
EPS (Rs.)-53.41-
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-16.92 - 38.14-
Debt / Equity (x)---
Operating margin (% of OI)34.134.934.2
Net margin (% of OI)26.224.525.1
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
159, CST Road
Kalina
Santacruz (East)
Mumbai
Maharashtra-400 098
PHONE
(022) 6640 2323
FAX
(022) 2652 8806
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer